



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C07D 401/04	A1	(11) International Publication Number: WO 00/63203 (43) International Publication Date: 26 October 2000 (26.10.00)
---	-----------	--

(21) International Application Number: PCT/CA99/00342

(22) International Filing Date: 21 April 1999 (21.04.99)

(71) Applicant: ALLELIX BIOPHARMACEUTICALS INC.
[CA/CA]; 6850 Goreway Drive, Mississauga, Ontario L4V 1V7 (CA).


(72) Inventors: SLASSI, Abdelmalik; 3237 Cambourne Crescent, Mississauga, Ontario L5N 5G4 (CA). EDWARDS, Louise; 35 Front Street S. #2008, Mississauga, Ontario L5H 2C6 (CA). O'BRIEN, Anne; 29 Glenlake Avenue, Upper Toronto, Ontario M6P 1E2 (CA). XIN, Tao; Apartment 1211, 40 Fountainhead Road, North York, Ontario M3J 2V1 (CA). TEHIM, Ashok; 7168 Sandhurst Drive, Mississauga, Ontario L5N 7H1 (CA).

(74) Agents: HIRONS, Robert, G. et al.; Ridout & Maybee, 18th floor, 150 Metcalfe Street, Ottawa, Ontario K2P 1P1 (CA).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

(54) Title: PIPERIDINE-INDOLE COMPOUNDS HAVING 5-HT₆ AFFINITY

(57) Abstract

Described herein are indole compounds with affinity for the 5-HT₆ receptor, which have general formula (I) wherein, R¹ is selected from the group consisting of H and C₁₋₄alkyl; R² is selected from the group consisting of H, C₁₋₄alkyl and benzyl; — represents a single or double bond; R³ is selected from the group consisting of COR⁵ and SO₂R⁵; R^{4a} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy; R^{4b} is selected from the group consisting of H, hydroxy, halo, C₃₋₇cycloalkyloxy, C₁₋₄alkoxy, C₁₋₄alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl; R^{4c} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy; R^{4d} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy; and R⁵ is selected from the group consisting of phenyl, pyridyl, thienyl, quinoliny and naphthyl which are optionally substituted with 1-4 substituents selected from C₁₋₄alkoxy, C₁₋₄alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl and C₁₋₄alkylS—. Also described is the use of the compounds as pharmaceuticals to treat indications where inhibition of the 5-HT₆ receptor is implicated, such as schizophrenia.

FOR THE PURPOSES OF INFORMATION ONLY


Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Piperidine-Indole Compounds Having 5-HT₆ Affinity

This invention relates to indole compounds having affinity for the serotonin 5-HT₆ receptor, to pharmaceutical compositions containing them
 5 and to their medical use, particularly in the treatment of CNS conditions.

According to one aspect of the invention, there are provided compounds of Formula I and salts, solvates or hydrates thereof:



10

wherein:

R¹ is selected from the group consisting of H and C₁₋₄alkyl;

R² is selected from the group consisting of H, C₁₋₄alkyl and benzyl;

15 ----- represents a single or double bond;

R³ is selected from the group consisting of COR⁵ and SO₂R⁵;

R^{4a} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy;

20 R^{4b} is selected from the group consisting of H, hydroxy, halo, C₃₋₇cycloalkyloxy, C₁₋₄alkoxy, C₁₋₄alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl;

R^{4c} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy;

25 R^{4d} is selected from the group consisting of H, OH, halo, C₁₋₄alkyl and C₁₋₄alkoxy; and

R⁵ is selected from the group consisting of phenyl, pyridyl, thienyl, quinolinyl and naphthyl which are optionally substituted with 1-4 substituents selected

from C₁₋₄alkoxy, C₁₋₄alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C₁₋₄alkylcarbonyl, C₁₋₄alkoxycarbonyl and C₁₋₄alkylS-.

According to another aspect of the invention, there is provided a
5 pharmaceutical composition comprising a compound of Formula I in an amount effective to antagonize the 5-HT₆ receptor, and a pharmaceutically acceptable carrier.

In another aspect of the present invention there are provided
10 compositions containing the present compounds in amounts for pharmaceutical use to treat CNS conditions where a 5-HT₆ ligand is indicated, for example, for the treatment or prevention of central nervous system disturbances such as psychosis, schizophrenia, manic depression, depression, neurological disturbances, memory disturbances, Parkinsonism,
15 amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease. These and other aspects of the present invention are described in greater detail hereinbelow.

Detailed Description and Preferred Embodiments

20

The term "C₁₋₄alkyl" as used herein means straight and branched chain alkyl radicals containing from one to four carbon atoms and includes methyl, ethyl, propyl, isopropyl, t-butyl and the like.

25 The term "C₁₋₄alkoxy" as used herein means straight and branched chain alkoxy radicals containing from one to four carbon atoms and includes methoxy, ethoxy, propyloxy, isopropyloxy, t-butoxy and the like.

The term "cycloalkyloxy" as used herein means saturated
30 carbocycloxy radicals containing from 3-7 carbon atoms and includes cyclopropyloxy, cyclohexyloxy and the like.

The term "1,2-methylenedioxy" as used herein means "-O-CH₂-O-" attached to adjacent nodes of a ring.

The term halo as used herein means halogen and includes fluoro, chloro, bromo and the like.

5 The term "pharmaceutically acceptable salt" means an acid addition salt which is compatible with the treatment of patients.

A "pharmaceutically acceptable acid addition salt" is any non-toxic organic or inorganic acid addition salt of the base compounds represented by
10 Formula I or any of its intermediates. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulfuric and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di- and tricarboxylic acids. Illustrative of such acids
15 are, for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxybenzoic, phenylacetic, cinnamic, salicylic, 2-phenoxybenzoic, p-toluenesulfonic acid and other sulfonic acids such as methanesulfonic acid and 2-hydroxyethanesulfonic acid. Either the mono- or di-acid salts can be
20 formed, and such salts can exist in either a hydrated, solvated or substantially anhydrous form. In general, the acid addition salts of these compounds are more soluble in water and various hydrophilic organic solvents, and generally demonstrate higher melting points in comparison to their free base forms. The selection criteria for the appropriate salt will be known to one skilled in the
25 art.

"Solvate" means a compound of Formula I or the pharmaceutically acceptable salt of a compound of Formula I wherein molecules of a suitable solvent are incorporated in a crystal lattice. A suitable solvent is
30 physiologically tolerable at the dosage administered as the solvate. Examples of suitable solvents are ethanol and the like.

The term "stereoisomers" is a general term for all isomers of the

individual molecules that differ only in the orientation of their atoms in space. It includes mirror image isomers (enantiomers), geometric (cis/trans) isomers and isomers of compounds with more than one chiral centre that are not mirror images of one another (diastereomers).

5

The term "treat" or "treating" means to alleviate symptoms, eliminate the causation of the symptoms either on a temporary or permanent basis, or to prevent or slow the appearance of symptoms of the named disorder or condition.

10

The term "therapeutically effective amount" means an amount of the compound which is effective in treating the named disorder or condition.

15

The term "pharmaceutically acceptable carrier" means a non-toxic solvent, dispersant, excipient, adjuvant or other material which is mixed with the active ingredient in order to permit the formation of a pharmaceutical composition, i.e., a dosage form capable of administration to the patient. One example of such a carrier is a pharmaceutically acceptable oil typically used for parenteral administration.

20

The term "schizophrenia" means schizophrenia, schizophreniform disorder, schizoaffective disorder and psychotic disorder wherein the term "psychotic" refers to delusions, prominent hallucinations, disorganized speech or disorganized or catatonic behavior. See Diagnostic and Statistical Manual of Mental Disorder, fourth edition, American Psychiatric Association, Washington, D.C.

The present invention includes within its scope prodrugs of the compounds of Formula I. In general, such prodrugs will be functional derivatives of the compounds of Formula I which are readily convertible *in vivo* into the required compound of Formula I. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs" ed. H. Bundgaard, Elsevier, 1985.

In embodiments of the invention, compounds of Formula I include those in which R^1 is selected from H and C_{1-4} alkyl. Preferably, R^1 is methyl. Also within the scope of the invention are compounds of Formula I wherein R^2 is selected from H, C_{1-4} alkyl and benzyl. In preferred embodiments, R^2 is H.

Compounds of the invention include Formula I compounds wherein R^3 is selected from COR^5 and SO_2R^5 . Within R^3 , R^5 is selected from phenyl, pyridyl, thienyl, quinoliny and naphthyl which are optionally substituted with 1-4 substituents selected from C_{1-4} alkoxy, C_{1-4} alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl and C_{1-4} alkylS-. When R^3 is COR^5 , R^5 is specifically selected from phenyl and thienyl optionally substituted with 1-2 groups independently selected from methyl, methoxy, halo and 1,2-methylenedioxy. In preferred embodiments, when R^3 is COR^5 , R^5 is phenyl, optionally substituted with 1-2 groups selected independently from halo, methoxy and methyl. When R^3 is SO_2R^5 , R^5 is specifically selected from phenyl, naphthyl and thienyl which are all optionally substituted with 1-3 groups independently selected from methyl, methoxy, halo, trifluoromethyl and 1,2-methylenedioxy. In preferred embodiments, when R^3 is SO_2R^5 , R^5 is selected from the group consisting of naphthyl and phenyl optionally substituted with 1-3 substituents independently selected from chloro, bromo, fluoro, nitro, methyl and methoxy. In more preferred embodiments, when R^3 is SO_2R^5 , R^5 is selected from the group consisting of phenyl, 2-chlorophenyl, 2-bromophenyl, 1-naphthyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 2,4-dichlorophenyl, 3-nitro-4-chlorophenyl, 2,4,6-trimethylphenyl, 4-methoxyphenyl and 4-methylphenyl.

In further embodiments of the invention, R^{4b} is selected from H, hydroxy, halo, C_{3-7} cycloalkyloxy, C_{1-4} alkoxy, C_{1-4} alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl. In specific embodiments, R^{4b} is selected from H, halo, cyclohexyloxy trifluoromethoxy and trifluoromethyl. Preferably, R^{4b} is selected from chloro, trifluoromethoxy, trifluoromethyl and fluoro.

In other embodiments of the invention, R^{4a} , R^{4c} and R^{4d} are each independently selected from H, OH, halo, C_{1-4} alkyl and C_{1-4} alkoxy. In specific embodiments, R^{4a} and R^{4c} are both H and R^{4d} is halo or R^{4c} is halo and R^{4a} , R^{4b} , R^{4d} are all H. In a preferred embodiment, R^{4a} , R^{4c} and R^{4d} are all H.

In another embodiment of the invention, ----- represents a single or double bond. Preferably ----- represents a double bond.

In embodiments of the invention, the compounds of Formula I include:

- 1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 15 1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 20 1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 25 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 30 1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;

- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole;
- 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5 6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 6-Bromo-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 10 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
- 15 1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Cyclohexyloxy-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 20 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
- 25 1-(4-Chloro-3-nitrophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitro-4-trifluoromethylphenylsulfonyl)indole;
- 30 1-(4-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

- 5-Cyclohexyloxy-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5 1-(4-t-Butylphenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
10 1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-t-Butylphenylsulfonyl)-4-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
15 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
20 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
25 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethoxyindole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
30 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-

- trifluoromethoxyindole;
 (4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride;
 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
 1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5-Cyclohexyloxy-1-(2,6-dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5-Cyclohexyloxy-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5-Cyclohexyloxy-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5-Cyclohexyloxy-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-Benzoyl-6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 6-Bromo-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 6-Bromo-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-thienoyl)indole;

- 1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole
hydrochloride;
- 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
- 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
5 trifluoromethoxyindole;
- 1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethoxyindole;
- 1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethoxyindole;
- 10 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole
hydrochloride;
- 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole;
- 1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
15 trifluoromethylindole;
- 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
- 5-Chloro-3-(1-methyl-4-piperidinyl)-1-phenylsulfonylindole;
- 5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
- 3-(1-Methyl-4-piperidinyl)-1-phenylsulfonylindole;
- 20 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
- 6-Chloro-3-(1-methyl-4-piperidinyl)-1-phenylsulfonylindole;
- 1-(4-Fluorophenylsulfonyl)-6-chloro-3-(1-methyl-4-piperidinyl)indole;
- 5-Fluoro-1-phenylsulfonyl-3-(1-methyl-4-piperidinyl)indole;
- 1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
- 25 1-Benzoyl-5-chloro-3-(1-methyl-4-piperidinyl)indole;
- 5-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
- 1-Benzoyl-3-(1-methyl-4-piperidinyl)indole;
- 1-(4-Fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
- 1-Benzoyl-6-chloro-3-(1-methyl-4-piperidinyl)indole;
- 30 6-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
- 1-Benzoyl-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
- 1-(4-Fluorobenzoyl)-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
- 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-vinylindole;

- 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole;
5,7-Difluoro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5 1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
10 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenyl)sulfonylindole;
15 5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole; and
1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.

20

In specific embodiments of the invention, the compounds of Formula I include:

- 1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
25 5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
30 1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

- 1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5 1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;
- 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 10 6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 6-Bromo-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 15 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
- 20 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
- 1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
- 25 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitro-4-trifluoromethylphenylsulfonyl)indole;
- 1-(4-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 30 5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Cyclohexyloxy-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

- 1-(4-Chlorophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 1-(4-t-Butylphenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5 1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 10 1-(4-t-Butylphenylsulfonyl)-4-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
- 15 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
- 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 20 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
- 5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
- 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethoxyindole;
- 25 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
- 1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
- 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
- 30 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
- (4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-

- trifluoromethoxyindole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-
trifluoromethylindole hydrochloride;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
5 trifluoromethylindole hydrochloride;
1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole hydrochloride;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole hydrochloride;
10 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole hydrochloride;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole hydrochloride;
1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-
15 pyridinyl)indole;
5-Cyclohexyloxy-1-(2,6-dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridinyl)indole;
5-Cyclohexyloxy-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-
4-pyridinyl)indole;
20 5-Cyclohexyloxy-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridinyl)indole;
1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole
hydrochloride;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
25 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethoxyindole;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethoxyindole;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole
30 hydrochloride;
1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-
trifluoromethylindole;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-

- trifluoromethylindole;
5-Chloro-3-(1-methyl-4-piperidiny)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-4-piperidiny)indole;
3-(1-Methyl-4-piperidiny)-1-phenylsulfonylindole;
5 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-4-piperidiny)indole;
1-(4-Fluorophenylsulfonyl)-6-chloro-3-(1-methyl-4-piperidiny)indole;
5-Fluoro-1-phenylsulfonyl-3-(1-methyl-4-piperidiny)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-(4-
10 methylphenylsulfonyl)indole;
5,7-Difluoro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole;
1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole;
15 1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-(1-
naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-(2-
20 naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-(2,4,6-
trimethylphenyl)sulfonylindole;
5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole; and
25 1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole.

In more specific embodiments of the invention, the compounds of
Formula I include:

- 30 5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-
pyridiny)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole;

- 1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
10 1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;
15 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
20 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
25 1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
30 1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

- 1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
5 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
10 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
15 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
20 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
25 1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole hydrochloride;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole;
30 trifluoromethylindole;
3-(1-Methyl-4-piperidinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-

- methylphenylsulfonyl)indole;
1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole; and
1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.
- 15 In the most specific embodiments of the invention, the compounds of Formula I include:
- 5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;

- 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
 5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride;
 1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole;
 1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole; and
 5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.

25

Acid addition salts of the compounds of Formula I are most suitably formed from pharmaceutically acceptable acids, and include for example those formed with inorganic acids e.g. hydrochloric, sulfuric or phosphoric acids and organic acids e.g. succinic, maleic, acetic or fumaric acid. Other non-pharmaceutically acceptable salts e.g. oxalates may be used for example in the isolation of compounds of Formula I for laboratory use, or for subsequent conversion to a pharmaceutically acceptable acid addition salt. Also included within the scope of the invention are solvates and hydrates of the invention.

30


The conversion of a given compound salt to a desired compound salt is achieved by applying standard techniques, in which an aqueous solution of the given salt is treated with a solution of base e.g. sodium carbonate or potassium hydroxide, to liberate the free base which is then extracted into an appropriate solvent, such as ether. The free base is then separated from the aqueous portion, dried, and treated with the requisite acid to give the desired salt.

Compounds of the present invention may have within its structure a chiral centre. The invention extends to cover all structural and optical isomers of the various compounds, as well as racemic mixtures thereof.

In accordance with other aspects of the invention, the compounds of the present invention can be prepared by processes analogous to those established in the art. For example, as shown in Scheme 1, compounds of Formula I may be prepared by first treating compounds of Formula A, wherein R^1 is C_{1-4} alkyl and R^2 and R^{4a-d} are as defined in Formula I, with an appropriate base, followed by the addition of a reagent of either Formula B or C, which provides a compound of Formula I wherein R^3 is SO_2R^5 or COR^5 , respectively. Therefore, for example, treatment of compounds of Formula A with a strong base such as lithium diisopropylamide, n-butyllithium or sodium bis(trimethylsilyl)amide in an inert solvent such as tetrahydrofuran or hexanes at a temperature in the range of -100 to 0 °C or, alternatively an organic amine in the presence of 4-dimethylaminopyridine (DMAP), in an inert solvent such as methylene chloride or chloroform, at a temperature in the range of 0 - 60 °C, followed by the addition of acid chlorides of Formula B or sulfonyl chlorides of Formula C, wherein R^5 is as defined in Formula I, provides compounds of Formula I wherein R^3 is COR^5 or SO_2R^5 respectively. Preferred conditions are sodium bis(trimethylsilyl)amide in tetrahydrofuran at -78 °C followed by warming to room temperature or triethylamine and DMAP in methylene chloride at room temperature. Reagents B and C are commercially available or can be prepared using standard methods known to those skilled in the art. The preparation of compounds of Formula A is

described below.

Scheme 1




5 Compounds of Formula I wherein R¹ is H may be prepared by treating a compound of Formula A, wherein R¹ is a suitable protecting group such as t-butoxycarbonyl (t-BOC), with reagents of Formula A or B as described above. Removal of the protecting group may be performed under standard conditions, for example using acidic conditions such as HCl in ethyl acetate to
 10 remove the t-BOC group, to provide compounds of Formula I wherein R¹ is H.

Compounds of Formula I, wherein R² is selected from C₁₋₄alkyl and benzyl, R¹ is C₁₋₄alkyl, R³ is SO₂R⁵ and R^{4a-d} are as defined in Formula I, may also be prepared by treating compounds of Formula I, wherein R² is H, R¹ is
 15 selected from C₁₋₄alkyl, R³ is SO₂R⁵ and R^{4a-d} are as defined in Formula I, with a strong base, such as n-butyllithium, in an inert solvent, such as tetrahydrofuran, at a temperature in the range of -100-0 °C (preferably -78 °C), followed by the addition of a reagent of formula R²-X, wherein R² is
 20 selected from C₁₋₄alkyl and benzyl and X is a suitable leaving group such as bromo, followed by warming to room temperature. The above reaction may also be carried out on a compound of Formula I, wherein R² is H, R¹ is a suitable protecting group, such as t-butoxycarbonyl, R³ is SO₂R⁵ and R^{4a-d} are
 25 as defined in Formula I, which, after removal of the protecting group using standard deprotection conditions (for example HCl in ethyl acetate to remove the t-butoxycarbonyl protecting group), provides a compound of Formula I wherein R² is selected from C₁₋₄alkyl and benzyl, R¹ is H, R³ is SO₂R⁵ and R^{4a-c}

are as defined in Formula I.

Compounds of Formula A wherein R^1 , R^2 and R^{4a-d} are as defined in Formula I may be prepared as shown in Scheme 2. Indole D, wherein R^2 and R^{4a-d} are as defined in Formula I, may be condensed with a reagent of Formula E, wherein R^1 is as defined in Formula I, in the presence of a base in a suitable solvent at temperatures in the range of 25-100 °C, preferably, 60-90 °C to provide compounds of Formula A wherein R^1 , R^2 , R^{4a-d} are as defined in Formula I and ----- represents a double bond. Suitable bases include organic amines such as pyrrolidine or triethylamine and suitable solvents include methanol, ethanol and the like. Preferred conditions are pyrrolidine in ethanol at a refluxing temperature. Compounds of Formula A, wherein R^1 , R^2 , R^{4a-d} are as defined in Formula I and ----- represents a double bond, may be reduced using standard hydrogenation conditions or using metal hydride reducing reagents to provide compounds of Formula A where R^1 , R^2 , R^{4a-d} are as defined in Formula I and ----- represents a single bond as shown in Scheme 2. Preferred is reduction by hydrogenation, using a suitable catalyst such as palladium or platinum on carbon in methanol at room temperature.

Scheme 2




Reagents of Formula A, wherein R^1 is a protecting group and R^2 and R^{4a-d} are as defined in Formula I, are available by treating reagents of Formula A, wherein R^1 is H, R^2 and R^{4a-d} are as defined in Formula I and ----- represents a single or double bond, under standard conditions to introduce a protecting group on the piperidine or tetrahydropyridine nitrogen. For example, reaction of indole A, wherein R^1 is H, in the presence of di-*t*-butyldicarbonate and a base, such as sodium hydroxide, would provide compounds of Formula A wherein R^1 is the *t*-BOC protecting group, R^2 and R^{4a-d} are as defined in Formula I and ----- represents a single or double bond.

The indoles of Formula D are either commercially available or can be prepared using standard procedures. For example, compounds of Formula D may be prepared as shown in Scheme 3. 4-Substituted anilines of Formula E, wherein R^{4a-d} are as defined in Formula I, can be treated with reagents of Formula F, wherein R^2 is as defined in Formula I, in the presence of a base such as sodium bicarbonate or potassium carbonate in an alcoholic solvent at temperatures in the range of 60-100 °C, to provide intermediates of Formula

G. Preferred conditions are sodium bicarbonate in ethanol at around 80 °C. Intermediates of Formula G can be cyclized in the presence of reagents of Formula H, wherein R is, for example, methyl or trifluoromethyl (which is preferred) at temperatures in the range of 60-100 °C, to provide indoles of Formula J. The preferred conditions are trifluoroacetic anhydride and trifluoroacetic acid at refluxing temperatures. Finally, compounds of Formula J can be treated under standard deprotection conditions, for example alkali hydroxides in an alcoholic solvent, to provide indoles of Formula D, wherein R² and R^{4a-d} are as defined in Formula I. Preferred conditions for this reaction are potassium hydroxide in ethanol at room temperature. The reagents of Formula E and F, are either commercially available or can be prepared using processes analogous to those established in the art.

Scheme 3




An alternative procedure for preparing indoles of Formula D wherein R^{4b} is vinyl or ethyl is shown in Scheme 4. Indoles of Formula K, wherein Y is a suitable leaving group such as halo or triflate (preferably bromo) and R² is as defined in Formula I, can be coupled with a vinyl trialkylstannane of, for example, Formula L, under standard palladium-cross coupling conditions to

provide indoles of Formula D, wherein R^{4b} is vinyl and R^2 is as defined in Formula I. It will be appreciated that other metal coupling reagents could be used in place of the vinyl stannane, for example, a vinyl boronic acid, chloro zinc and the like. Preferred coupling conditions include heating the indole and vinyl metal reagent in an inert solvent such as dimethylformamide or toluene in the presence of tetrakis(triphenylphosphine) palladium (0) at refluxing temperatures. Following the coupling reaction, the double bond of the vinyl group can be hydrogenated using catalytic amounts of palladium on carbon in an inert solvent (preferably ethyl acetate) in a hydrogen atmosphere at room temperature to provide indoles of Formula D wherein R^{4b} is ethyl. This procedure could also be used to prepare compounds of Formula D wherein R^{4a} , R^{4c} or R^{4d} are ethyl by reacting the appropriately substituted indole L as described above.

15


Scheme 4



Indoles of Formula D, wherein R^{4b} is cyclooxy or phenoxy and R^2 is as defined in Formula I, are also available from the corresponding 5-hydroxyindole M as shown in Scheme 5. Reaction of indole M with, for example, cyclohexanol N under standard Mitsunobu conditions (Mitsunobu, O. *Synthesis*, 1981:1-28) provides reagents of Formula D, wherein R^{4b} is cyclohexyloxy and R^2 is as defined as Formula I. Reaction of indole M with reagent of Formula O wherein Y is an appropriate leaving group such as halo,

preferably iodo, under standard Ullman conditions (Fanta, F. E., *Chem. Rev.*, **64**, 1964:613) provides indoles of Formula D, wherein R^{4b} is phenoxy and R^2 is as defined in Formula I. Preferred conditions are iodobenzene in the presence of potassium carbonate, copper (I) bromide and copper powder in
5 N-methylpyrrolidine at 170 °C.

Scheme 5



10

The reactions shown in Schemes 4 and 5 could also be applied to indoles with the 3-position group in place. In some cases, the chemistries outlined above may have to be modified, for instance by use of protecting groups, to prevent side reactions due to reactive groups, such as reactive
15 groups attached as substituents.

In another embodiment of the invention, the present compounds can be used to distinguish 5-HT₆ receptors from other receptor subtypes, for example glutamate or opioid receptors, within a population of receptors, and in particular
20 to distinguish between the 5-HT₆ and other 5-HT receptor subtypes. The latter can be achieved by incubating preparations of the 5-HT₆ receptor and one of the other 5-HT receptor subtypes (for example 5-HT_{2A}) with a 5-HT₆-selective compound of the invention and then incubating the resulting preparation with a

radiolabeled serotonin receptor ligand, for example [³H]-serotonin. The 5-HT₆ receptors are then distinguished by determining the difference in membrane-bound activity, with the 5-HT₆ receptor exhibiting lesser radioactivity, i.e., lesser [³H]-serotonin binding, than the other 5-HT receptor subtype.

5

In another embodiment of the invention, the compound is provided in labeled form, such as radiolabeled form, e. g. labeled by incorporation within its structure ³H or ¹⁴C or by conjugation to ¹²⁵I. In another aspect of the invention, the compounds in labeled form can be used to identify 5-HT₆ receptor ligands by techniques common in the art. This can be achieved by incubating the receptor or tissue in the presence of a ligand candidate and then incubating the resulting preparation with an equimolar amount of radiolabeled compound of the invention such as [³H]-5-fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole. 5-HT₆ receptor ligands are thus revealed as those that are not significantly displaced by the radiolabeled compound of the present invention. Alternatively, 5-HT₆ receptor ligand candidates may be identified by first incubating a radiolabeled form of a compound of the invention then incubating the resulting preparation in the presence of the candidate ligand. A more potent 5-HT₆ receptor ligand will, at equimolar concentration, displace the radiolabeled compound of the invention.

The present compounds are useful as pharmaceuticals for the treatment of various conditions in which the use of a 5-HT₆ antagonist is indicated, such as psychosis, schizophrenia, manic depression, depression, neurological disturbances, memory disturbances, Parkinsonism, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease. In another of its aspects, the present invention provides pharmaceutical compositions useful to treat 5-HT₆-related medical conditions, in which a compound of Formula I is present in an amount effective to antagonize 5-HT₆ receptor stimulation, together with a pharmaceutically acceptable carrier. In a related aspect, the invention provides a method for treating medical conditions for which a 5-HT₆ receptor antagonist is indicated, which comprises the step of

administering to the patient an amount of a compound of Formula I effective to antagonize 5-HT₆ receptor stimulation, and a pharmaceutically acceptable carrier therefor.

5 For use in medicine, the compounds of the present invention can be administered in a standard pharmaceutical composition. The present invention therefore provides, in a further aspect, pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a Formula I compound or a pharmaceutically acceptable salt, solvate or hydrate thereof, in an amount
10 effective to treat the target indication.

 The compounds of the present invention may be administered by any convenient route, for example by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and the pharmaceutical
15 compositions formulated accordingly.

 Compounds of Formula I and their pharmaceutically acceptable salts which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, or as solid forms such as tablets, capsules
20 and lozenges. A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable pharmaceutical liquid carrier for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavouring or colouring agent. A composition in the form of a
25 tablet can be prepared using any suitable pharmaceutical carrier routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose. A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using
30 standard carriers and then filled into hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier, for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension filled into a soft gelatin capsule.

Typical parenteral compositions consist of a solution or suspension of the compound or pharmaceutically acceptable salt in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilized and then reconstituted with a suitable solvent just prior to administration.

Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively, the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer.

Compositions suitable for buccal or sublingual administration include tablets, lozenges, and pastilles, wherein the active ingredient is formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine. Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.

Preferably, the composition is in unit dose form such as a tablet, capsule or ampoule. Suitable unit dosages, i.e. therapeutically effective amounts, can be determined during clinical trials designed appropriately for each of the conditions for which administration of a chosen compound is indicated and will of course vary depending on the desired clinical endpoint. Each dosage unit for

oral administration may contain from 0.01 to 500 mg/kg (and for parenteral administration may contain from 0.1 to 50 mg) of a compound of Formula I, or a pharmaceutically acceptable salt thereof calculated as the free base, and will be administered in a frequency appropriate for initial and maintenance treatments. For laboratory use, the present compounds can be stored in packaged form for reconstitution and use.

Experimental Examples

10 Example 1: 5-Cyclohexyloxy-1H-indole:

Triphenylphosphine (10.3 g, 39.4 mmol) and 5-hydroxy-1H-indole (5 g, 36.9 mmol) were added to a solution of cyclohexanol (3.7 mL, 35.7 mmol) in THF (200 mL) at 0 °C. DEAD (5.9 mL, 39.4 mmol) was slowly added and the resulting solution was stirred for 1 week at room temperature. The solvent was removed *in vacuo* and flash chromatography (silica gel, 10% ethyl acetate in hexane) yielded 5-cyclohexyloxy-1H-indole (3.2 g, 40%).

Example 2: 5-Trifluoromethoxy-1H-indole

20

Lithium aluminum hydride (10.4 mL, 1M in THF, 10.4 mmol) was added to a solution of 5-trifluoromethoxyisatin (0.8 g, 3.45 mmol) in THF at room temperature and the mixture was refluxed overnight. The reaction mixture was cooled, and Na₂SO₄·10H₂O was added very carefully portionwise, followed by ethyl acetate. The reaction mixture was then filtered, and the filtrate was evaporated. The residual oil was purified by column chromatography with ethyl acetate in hexanes (2:98) to yield 5-trifluoromethoxy-1H-indole (0.162 g, 23%).

30 Example 3: 5,7-Difluoro-1H-indole

Vinylmagnesium bromide (30 mL, 1M in THF, 30 mmol) was added dropwise to a solution of 2,4-difluoronitrobenzene (1.6 g, 10 mmol) in THF at - 40 °C.

The mixture was stirred for 30 min and then poured into CH₂Cl₂-diluted HCl. The organic layer was separated and dried (Na₂SO₄). After the solvent was removed *in vacuo*, the residual oil was purified by column chromatography with EtOAc/Hexanes (2:98) to yield 2,4-difluoro-1H-indole (189 mg, 12%).

5

Example 4(a): 5-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole

5-Bromo-1H-indole (4.31 g, 22 mmol), 1-methyl-4-piperidone (2.46 mL, 20 mmol) and pyrrolidine (17 mL, 200 mmol) were mixed in ethanol (30 mL) and
10 refluxed for 72 hours. The mixture was cooled to room temperature and the resulting solid, collected by filtration, washed with methanol and dried to provide the title compound as a white solid (4.40 g, 76%). mp >230 °C, dec.

In a like manner, the following additional compounds were prepared:

15

(b) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: from 5-fluoro-1H-indole;

(c) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole:
20 from 5-cyclohexyloxy-1H-indole (Example 1);

(d) 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: from 5-chloro-1H-indole;

25 (e) 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: from 1H-indole;

(f) 6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: from 6-bromo-1H-indole;

30 (g) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: (176.8 mg, 58%); from 5,7-difluoroindole (Example 3, 188 mg, 1.23 mmol) and N-methyl-4-piperidone (153.4 mg, 1.23 mmol) with pyrrolidine (875 mg, 12.3 mmol) in ethanol (1.5 mL) at reflux. m.p 215-21 °C, HRMS-FAB⁺ for

$C_{14}H_{14}N_2F_2$: calc.MH⁺: 249.12033 ; found:249.12095;

(h) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole:
from 5-trifluoromethoxy-1H-indole (Example 2);

5

(i) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole: from
5-trifluoromethyl-1H-indole (prepared according to Miyano, *et al.*, JP-
60204759);

10 (j) 6-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole: from 6-
chloro-1H-indole.

Example 5(a): 5-Cyclohexyloxy-3-(1-methyl-4-piperidinyl)-1H-indole

15 Palladium on carbon (10%, 31 mg) was added to a solution of 5-
cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example
4c, 48.4 mg, 0.16 mmol) in methanol (5 mL) and the mixture was stirred under
an atmosphere of hydrogen for 8h. Removal of the catalyst by filtration
through celite and silica (20% 2M methanolic ammonia in dichloromethane)
20 yielded 5-cyclohexyloxy-3-(1-methyl-4-piperidinyl)-1H-indole (quantitative,
HRMS-FAB⁺ for $C_{20}H_{28}N_2O$: calculated MH⁺:313.22800; found
MH⁺:313.23083).

In a like manner, the following additional compounds were prepared:

25

(b) 6-Chloro-3-(1-methyl-4-piperidinyl)-1H-indole: (0.815 g, 81%); from 6-
chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4j, 1.0
g, 4 mmol) and 5% Pt/C (0.78 g, 0.2 mmol) in ethanol under H₂; m.pt. 218-
24°C.

30

(c) 5-Fluoro-3-(1-methyl-4-piperidinyl)-1H-indole: (0.64 g, 64%); from 5-fluoro-
3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 1.0 g, 4.34
mmol) and 5% Pt/C(0.43 g, 0.4 mmol) in ethanol under H₂; mp 158-61°C.

HRMS-FAB⁺ for C₁₄H₁₇N₂F calculated MH⁺: 233.14540, found: 233.13193.

(d) 3-(1-Methyl-4-piperidiny)-1H-indole: (0.92 g, 91%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1H-indole (Example 4e, 1.0 g, 4.69 mmol) and
5 10% Pd/C on carbon (0.5 g, 0.47 mmol) in ethanol under H₂; mp 174-6°C;
HRMS-FAB⁺ for C₁₄H₁₈N₂, calculated MH⁺: 215.15483, found: 215.15356.

(e) 5-Chloro-3-(1-methyl-4-piperidiny)indole: (0.89 g, 88%); from 5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole (Example 4d, 1.0 g, 4 mmol)
10 and 5% Pt/C (0.78 g, 0.2mmol) in methanol under H₂; mp 192-4°C; HRMS-FAB⁺ for C₁₄H₁₇N₂Cl calculated MH⁺: 249.11584, found: 249.11529.

Example 6(a): 1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole

15

Benzoyl chloride (33.3 mg, 0.24 mmol) was added to a solution of 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole (Example 4b, 49.6 mg, 0.215 mmol), triethylamine (0.15 mL, 1.1 mmol) and DMAP (5 mg) in dichloromethane (2 mL). The mixture was stirred at room temperature prior to
20 quenching with water and extraction into dichloromethane. The organic layer was washed with brine and dried over sodium sulfate. Purification by flash chromatography (silica gel, 2M methanolic ammonia in chloroform) yielded 1-benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole (27.8 mg, 39%, HRMS-FAB⁺ for C₂₁H₂₀N₂OF calculated MH⁺: 335.15598; found:
25 335.15457).

In a like manner, the following additional compounds were prepared:

(b) 5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole: (7.2 mg, 8%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)indole (Example 4b, 52.0 mg, 0.226 mmol) and 4-methylphenylsulfonyl chloride (48.0 mg, 0.25 mmol); HRMS-FAB⁺ for C₂₁H₂₂N₂O₂SF: calculated MH⁺: 385.13861; found: 385.14053.

- (c) 1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (21 mg, 34%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4b, 37.2 mg, 0.62 mmol) and 2-chlorobenzoyl chloride (28.3 mg, 0.19 mmol); HRMS-FAB⁺ for C₂₁H₁₉N₂OClF: calculated MH⁺ 369.11700; found: 369.11418.
- (d) 5-Fluoro-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (30.2 mg, 64%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4b, 29.9 mg, 0.15 mmol) and 4-methoxybenzoyl chloride (22.2 mg, 0.16 mmol); HRMS-FAB⁺ for C₂₂H₂₂N₂O₂F: calculated MH⁺ 365.16653; found: 365.16747.
- (e) 5-Fluoro-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (11.1 mg, 20%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4b, 33.8 mg, 0.147 mmol) and 3,4-methylenedioxybenzoyl chloride (27.1 mg, 0.176 mmol); HRMS-FAB⁺ for C₂₂H₂₀N₂O₃F calculated MH⁺: 379.14578; found: 379.14399.

(f) 1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (20.6 mg, 32%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4b, 36.8 mg, 0.160 mmol) and 2,6-dichlorobenzoyl chloride (33.5 mg, 0.19 mmol); HRMS-FAB⁺ for C₂₁H₁₈N₂OCl₂F calculated MH⁺: 403.07803; found: 403.08101.

(g) 1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (442 mg, 65%), from 5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4a, 500 mg, 1.72 mmol) and benzoyl chloride (239 μ L, 2.06 mmol).

Example 7(a): 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole

Sodium bis(trimethylsilyl)amide (0.23 mL, 1M in THF, 0.23 mmol) was added to a solution of 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 4e, 25.0 mg, 0.12 mmol) in THF (1.5 mL) at -78 °C and the mixture was stirred for 1 h. Phenylsulfonyl chloride (30 μ L, 0.24 mmol) was added and the mixture stirred at room temperature for 2h. prior to quenching with water (4 drops) and silica gel (~1g). Purification using solid phase extraction tubes (1000 mg silica, eluting with 0-10% 2M methanolic ammonia in dichloromethane) yielded 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole (9.0 mg, 22%, HRMS-FAB⁺ for C₂₀H₂₀N₂O₂S: calculated MH⁺: 353.13239; found: 353.13235).

In a like manner, the following additional compounds were prepared:

(b) 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (9.0 mg, 20%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4e, 24.8 mg, 0.12 mmol) and 4-methoxyphenylsulfonyl chloride (48.2 mg, 0.23 mmol); HRMS-FAB⁺ for C₂₁H₂₂N₂O₃S: calculated MH⁺: 383.14294; found: 383.14276.

(c) 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-

- pyridinyl)indole: (9.0 mg, 21%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4e, 24.8 mg, 0.12 mmol) and 4-fluorophenylsulfonyl chloride (46.5 mg, 0.24 mmol); HRMS-FAB⁺ for C₂₀H₁₉N₂O₂SF: calculated MH⁺: 371.12296; found: 371.12323.
- 5 (d) 1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (43.8 mg, 90%); from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 25.0 mg, 0.108 mmol) and 4-bromophenylsulfonyl chloride (56.4 mg, 0.22 mmol); HRMS-FAB⁺ for
- 10 C₂₀H₁₈N₂O₂SFBr: calculated MH⁺: 449.03348; found: 449.03297.
- (e) 5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (36.5 mg, 76%); from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 25.3 mg, 0.110 mmol) and 2,5-
- 15 dichlorophenylsulfonyl chloride (55.6 mg, 0.23 mmol); HRMS-FAB⁺ for C₂₀H₁₇N₂O₂SFCl₂: calculated MH⁺: 439.04501; found: 439.04294.
- (f) 1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (39.1 mg, 79%); from 5-fluoro-3-(1-methyl-1,2,3,6-
- 20 tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 25.4 mg, 0.110 mmol) and 4-chloro-3-nitrophenylsulfonyl chloride (57.6 mg, 0.22 mmol); HRMS-FAB⁺ for C₂₀H₁₇N₂O₄SFCl: calculated MH⁺: 450.06906; found: 450.07176.
- (g) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-
- 25 trimethylphenylsulfonyl)indole: (34.7 mg, 76%); from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 25.5 mg, 0.110 mmol) and 2,4,6-trimethylphenylsulfonyl chloride (48.4 mg, 0.22 mmol); HRMS-FAB⁺ for C₂₃H₂₅N₂O₂SF: calculated MH⁺: 413.16989; found: 413.17396.
- 30 (h) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole: (25.8 mg, 48%); from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 24.9 mg, 0.108 mmol) and 2,4,6-triisopropylphenylsulfonyl chloride (68.8 mg, 0.23 mmol); HRMS-FAB⁺

for $C_{29}H_{37}N_2O_2SF$: calculated MH^+ : 497.26379; found: 497.26112.

5 (i) 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (49.0 mg, 94%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 35.0 mg, 0.112 mmol) and 4-methylphenylsulfonyl chloride (41 mg, 0.22 mmol); HRMS-FAB⁺ for $C_{27}H_{32}N_2O_3S$: calculated MH^+ : 465.22119; found: 465.22309.

10 (j) 6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole: (23.9 mg, 64%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 25.0 mg, 0.086 mmol) and phenylsulfonyl chloride (22 μ L, 0.17 mmol); HRMS-FAB⁺ for $C_{20}H_{19}N_2O_2BrS$: calculated MH^+ : 431.04288; found: 431.04656.

15 (k) 6-Bromo-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (24.5 mg, 62%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 25.0 mg, 0.086 mmol) and 4-methoxyphenylsulfonyl chloride (35 mg, 0.17 mmol); HRMS-FAB⁺ for $C_{21}H_{21}N_2O_3BrS$: calculated MH^+ : 461.05344; found: 461.04886.

20 (l) 6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (20.9 mg, 54%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 25.1 mg, 0.086 mmol) and 4-fluorophenylsulfonyl chloride (35 mg, 0.18 mmol); HRMS-FAB⁺ for $C_{20}H_{18}N_2O_2BrSF$: calculated MH^+ : 449.03348; found: 449.02907.

25 (m) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole: (34.1 mg, 92%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.6 mg, 0.082 mmol) and phenylsulfonyl chloride (20 μ L, 0.157 mmol); HRMS-FAB⁺ for $C_{26}H_{30}N_2O_3S$: calculated MH^+ : 451.20554; found: 451.20922.

(n) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-

naphthylsulfonyl)indole: (35.9 mg, 87%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.5 mg, 0.082 mmol) and 1-naphthylsulfonyl chloride (37.7 mg, 0.17 mmol); HRMS-FAB⁺ for C₃₀H₃₂N₂O₃S: calculated MH⁺: 501.22119; found: 501.21807.

5

(o) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole: (37.4 mg, 92%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.2 mg, 0.081 mmol) and 2-naphthylsulfonyl chloride (38.5 mg, 0.17 mmol); HRMS-FAB⁺ for

10 C₃₀H₃₂N₂O₃S: calculated MH⁺: 501.22119; found: 501.22101.

(p) 1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (34.4 mg, 82%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 24.5 mg, 0.079 mmol) and 2-bromophenylsulfonyl chloride (40.2 mg, 0.16 mmol); HRMS-FAB⁺ for C₂₆H₂₉N₂O₃SBr: calculated MH⁺: 529.11603; found: 529.11380.

15

(q) 5-Cyclohexyloxy-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (37.3 mg, 89%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.5 mg, 0.082 mmol) and 2,5-dichlorophenylsulfonyl chloride (42.0 mg, 0.17 mmol); HRMS-FAB⁺ for C₂₆H₂₈N₂O₃SCl₂: calculated MH⁺: 519.12762; found: 519.12579.

20

(r) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole: (31.6 mg, 78%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.5 mg, 0.082 mmol) 2,4,6-trimethylphenylsulfonyl chloride (36.8 mg, 0.17 mmol); HRMS-FAB⁺ for C₂₉H₃₆N₂O₃S: calculated MH⁺: 493.25250; found: 493.25329.

25

(s) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole: (23.3 mg, 50%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.2 mg, 0.081 mmol) 2,4,6-triisopropylphenylsulfonyl chloride (53.7 mg, 0.18 mmol); HRMS-

30

FAB⁺ for C₃₅H₄₈N₂O₃S: calculated MH⁺: 577.34637; found: 577.34710.

(t) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole: (38.0 mg, 96%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 24.8 mg, 0.080 mmol) and 3-nitrophenylsulfonyl chloride (35.3 mg, 0.159 mmol); HRMS-FAB⁺ for C₂₆H₂₉N₃O₅S: calculated MH⁺: 496.19061; found: 496.19042.

(u) 1-(4-Chloro-3-nitrophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (37.4 mg, 87%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.1 mg, 0.081 mmol) and 4-chloro-3-nitrophenylsulfonyl chloride (42.7 mg, 0.17 mmol); HRMS-FAB⁺ for C₂₆H₂₈N₃O₅SCl: calculated MH⁺: 530.15167; found: 530.14727.

(v) 5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitro-4-trifluoromethylphenylsulfonyl)indole: (33.9 mg, 75%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 24.8 mg, 0.080 mmol) and 3-nitro-4-trifluoromethylphenylsulfonyl chloride (48.4 mg, 0.167 mmol); HRMS-FAB⁺ for C₂₇H₂₈N₃O₅SF₃: calculated MH⁺: 564.17798; found: 564.17855.

(w) 1-(4-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (31.4 mg, 72%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.7 mg, 0.083 mmol) and 4-bromophenylsulfonyl chloride (43 mg, 0.17 mmol); HRMS-FAB⁺ for C₂₆H₂₉N₂O₃SBr: calculated MH⁺: 529.11603; found: 529.11817.

(x) 5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (34.8 mg, 89%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.2 mg, 0.081 mmol) and 4-methoxyphenylsulfonyl chloride (34.1 mg, 0.165 mmol); HRMS-FAB⁺ for C₂₇H₃₂N₂O₄S: calculated MH⁺: 481.21609; found: 481.21625.

(y) 5-Cyclohexyloxy-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (34.0 mg, 88%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.5 mg, 0.082 mmol) and 4-fluorophenylsulfonyl chloride (30.8 mg, 0.16 mmol); HRMS-FAB⁺ for C₂₆H₂₉N₂O₃SF: calculated MH⁺: 469.19611; found: 469.19626.

(z) 1-(4-Chlorophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (37.7 mg, 94%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.5 mg, 0.082 mmol) and 4-chlorophenylsulfonyl chloride (35.6 mg, 0.169 mmol); HRMS-FAB⁺ for C₂₆H₂₉N₂O₃SCl: calculated MH⁺: 485.16656; found: 485.16480.

(aa) 1-(4-t-Butylphenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (34.0 mg, 81%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.6 mg, 0.082 mmol) and 4-t-butylphenylsulfonyl chloride (37.2 mg, 0.16 mmol); HRMS-FAB⁺ for C₃₀H₃₈N₂O₃S: calculated MH⁺: 507.26813; found: 507.27183.

(bb) 1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (32 mg, 53%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 30.6 mg, 0.133 mmol) and 2-bromophenylsulfonyl chloride (67.9 mg, 0.27 mmol); HRMS-FAB⁺ for C₂₀H₁₉N₂SO₂BrF calculated MH⁺: 449.03348; found: 449.03240.

25

(cc) 1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (30 mg, 57%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b) and 4-fluorophenylsulfonyl chloride (52.9 mg, 0.27 mmol); HRMS-FAB⁺ for C₂₀H₁₉N₂O₂SF₂ calculated MH⁺: 389.11353; found: 389.11544.

30

(dd) 1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (28.1 mg, 53%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-

- 4-pyridinyl)-1H-indole (Example 4b, 30.1 mg, 0.131 mmol) and 4-chlorophenylsulfonyl chloride (55.3 mg, 0.26 mmol); HRMS-FAB⁺ for C₂₀H₁₉N₂O₂SClF calculated MH⁺: 405.08998; found: 405.08291.
- 5 (ee) 1-(4-t-Butylphenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (23.0 mg, 42%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 29.4 mg, 0.128 mmol) and 4-t-butylphenylsulfonyl chloride (59.6 mg, 0.26 mmol); HRMS-FAB⁺ for C₂₄H₂₈N₂O₂SF calculated MH⁺: 427.18555; found: 427.18680.
- 10 (ff) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole: (31.0 mg, 56%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 30.1 mg, 0.131 mmol) and 3-nitrophenylsulfonyl chloride (58.1 mg, 0.26 mmol); HRMS-FAB⁺ for
- 15 C₂₀H₁₉N₃O₄SF calculated MH⁺: 416.10803; found: 416.10631.
- (gg) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole: (28.2 mg, 52%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 29.4 mg, 0.128 mmol) and 1-
- 20 naphthylsulfonyl chloride (58 mg, 0.26 mmol); HRMS-FAB⁺ for C₂₄H₂₂N₂O₂SF calculated MH⁺: 421.13861; found: 421.14099.
- (hh) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole: (32.3 mg, 56%), from 5-fluoro-3-(1-methyl-1,2,3,6-
- 25 tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 31.4 mg, 0.136 mmol) and 2-naphthylsulfonyl chloride (61.7 mg, 0.27 mmol); HRMS-FAB⁺ for C₂₄H₂₂N₂O₂SF calculated MH⁺: 421.13861; found: 421.13866.
- (ii) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole:
- 30 (28.2 mg, 60%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 29.5 mg, 0.128 mmol) and phenylsulfonyl chloride (45.3 mg, 0.26 mmol); HRMS-FAB⁺ for C₂₀H₂₀N₂O₂SF calculated MH⁺: 371.12296; found: 371.12242.

(jj) 5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole: from 5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4d, 25 mg, 0.10 mmol) and phenylsulfonyl chloride (26.4 mg, 0.15 mmol).

- 5 The HCl salt (29.5 mg, 70%) was prepared from the crude product using 1M HCl in ether; m.p 245-8 °C, HRMS-FAB⁺ for C₂₀H₁₉N₂O₂SClHCl, calculated MH⁺(-HCl): 387.09341; found: 387.09262.

- (kk) 5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: from 5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4d, 25 mg, 0.1 mmol) and 4-fluorophenylsulfonyl chloride (29.1 mg, 0.15 mmol). The HCl salt ether (32.6 mg, 74%) was prepared from the crude product using 1M HCl in ether. m.p 256-7 °C, HRMS-FAB⁺ for C₂₀H₁₈N₂O₂SClF₄HCl, calculated MH⁺(-HCl): 405.08398; found: 405.0797.

15

- (ll) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and phenylsulfonyl chloride (18.9 mg, 0.11 mmol). The HCl salt (16.7 mg, 50%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₁H₁₉N₂O₃SF₃HCl, calculated MH⁺(-HCl): 437.11469; found: 437.11460.

20

- (mm) 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-fluorophenylsulfonyl chloride (20.8 mg, 0.11 mmol). The HCl salt (24.0 mg, 69%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₁H₁₈N₂O₃SF₄HCl, calculated MH⁺(-HCl): 455.10526; found: 455.10735.

25

30

- (nn) 1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-t-

butylphenylsulfonyl chloride (24.9 mg, 0.11 mmol). The HCl salt (9.4 mg, 25%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₅H₂₇N₂O₃SF₃·HCl, calculated MH⁺(-HCl): 493.17728; found: 493.17565.

5

(oo) 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-chlorophenylsulfonyl chloride (22.5 mg, 0.11 mmol). The HCl salt (21.8 mg, 60%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₁H₁₈N₂O₃SClF₃·HCl, calculated MH⁺(-HCl): 473.07275; found: 473.07154.

10

(pp) 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-methylphenylsulfonyl chloride (20.4 mg, 0.11 mmol). The HCl salt (17.0 mg, 49%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₂H₂₁N₂O₃SF₃·HCl, calculated MH⁺(-HCl): 451.13031; found: 451.12820.

15

20

(qq) (4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-methoxyphenylsulfonyl chloride (22.1 mg, 0.11 mmol). The HCl salt (15.8 mg, 44%) was prepared from the crude product using 1M HCl in ether. HRMS-FAB⁺ for C₂₂H₂₁N₂O₄SF₃·HCl, calculated MH⁺(-HCl): 467.12524; found: 467.12526.

25

(rr) 3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride: (14.9 mg, 46%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and phenylsulfonyl chloride (18.9 mg, 0.107 mmol). HRMS-FAB⁺ for

30

$C_{21}H_{19}N_2O_2SF_3 \cdot HCl$, calculated $MH^+(-HCl)$: 421.11975; found: 421.11923.

(ss) 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (15.0 mg, 44%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-fluorophenylsulfonyl chloride (20.8 mg, 0.107 mmol). HRMS-FAB⁺ for $C_{21}H_{18}N_2O_2SF_4 \cdot HCl$, calculated $MH^+(-HCl)$: 439.11035; found: 439.10807.

10 (tt) 1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (8.7 mg, 24%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-t-butylphenylsulfonyl chloride (24.9 mg, 0.11 mmol). HRMS-FAB⁺ for $C_{25}H_{27}N_2O_2SF_3 \cdot HCl$, calculated $MH^+(-HCl)$: 477.18237; found:
15 477.18134.

(uu) 1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (11.5 mg, 33%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-chlorophenylsulfonyl chloride (22.5 mg, 0.11 mmol). HRMS-FAB⁺ for $C_{21}H_{18}ClF_3N_2O_2S \cdot HCl$, calculated $MH^+(-HCl)$: 455.08078; found:
20 455.08266.

(vv) 1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (22.2 mg, 69%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-methoxyphenylsulfonyl chloride (22.1 mg, 0.107 mmol). HRMS-FAB⁺ for $C_{22}H_{21}N_2O_3SF_3 \cdot HCl$, calculated MH^+ : 451.13031; found: 451.13007.

30 (ww) 1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (14.8 mg, 48%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-methylphenylsulfonyl chloride (20.4 mg, 0.107 mmol). HRMS-

FAB⁺ for C₂₂H₂₁N₂O₂SF₃HCl, calculated MH⁺: 435.13541; found: 435.13700.

(xx) 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (9.3 mg, 25%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4e, 25.0 mg, 0.12 mmol) and benzoyl chloride (28 uL, 0.24 mmol); HRMS-FAB⁺ for C₂₁H₂₀N₂O: calculated MH⁺: 317.16537; found: 317.16518.

(yy) 1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (10.9 mg, 27%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4e, 24.8 mg, 0.12 mmol) and 4-methoxybenzoyl chloride (35 uL, 0.24 mmol); HRMS-FAB⁺ for C₂₂H₂₂N₂O₂: calculated MH⁺: 347.17596; found: 347.17819.

(zz) 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (8.7 mg, 22%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4e, 24.8 mg, 0.12 mmol) and 4-fluorobenzoyl chloride (28 uL, 0.24 mmol); HRMS-FAB⁺ for C₂₁H₁₉N₂O₂F: calculated MH⁺: 335.15598; found: 335.15560.

(aaa) 1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (12.5 mg, 33%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.7 mg, 0.083 mmol) and 2-chlorobenzoyl chloride (25 uL, 0.20 mmol); HRMS-FAB⁺ for C₂₇H₂₉N₂O₂Cl: calculated MH⁺: 449.19958; found: 449.19815.

25

(bbb) 5-Cyclohexyloxy-1-(2,6-dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (40.1 mg, 100%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.7 mg, 0.083 mmol) and 2,6-dichlorobenzoyl chloride (30 uL, 0.21 mmol); HRMS-FAB⁺ for C₂₇H₂₈N₂O₂Cl₂: calculated MH⁺: 483.16061; found: 483.15611.

30

(ccc) 5-Cyclohexyloxy-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (18.7 mg, 51%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-

tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.6 mg, 0.082 mmol) and 4-methoxybenzoyl chloride (30 μ L, 0.20 mmol); HRMS-FAB⁺ for C₂₈H₃₂N₂O₃: calculated MH⁺: 445.24911; found: 445.25149.

- 5 (ddd) 5-Cyclohexyloxy-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (19.0 mg, 50%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.6 mg, 0.082 mmol) and 3,4-methylenedioxybenzoyl chloride (37 mg, 0.20 mmol); HRMS-FAB⁺ for C₂₈H₃₀N₂O₄: calculated MH⁺: 459.22839; found: 459.22911.

10

(eee) 5-Cyclohexyloxy-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (24.0 mg, 68%); from 5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4c, 25.6 mg, 0.082 mmol) and 4-fluorobenzoyl chloride (25 μ L, 0.21 mmol); HRMS-FAB⁺ for C₂₇H₂₉N₂O₂F: calculated MH⁺: 433.22913; found: 433.22733.

15

(fff) 1-Benzoyl-6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (23.2 mg, 68%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 25.0 mg, 0.086 mmol) and benzoyl chloride (20 μ L, 0.17 mmol); HRMS-FAB⁺ for C₂₁H₁₉N₂OBr: calculated MH⁺: 395.07590; found: 395.07848.

20

- (ggg) 6-Bromo-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (17.4 mg, 48%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 25.0 mg, 0.086 mmol) and 4-methoxybenzoyl chloride (26 μ L, 0.17 mmol); HRMS-FAB⁺ for C₂₂H₂₁O₂ N₂Br calculated MH⁺: 425.08646; found: 425.08292.

25

- (hhh) 6-Bromo-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (24.7 mg, 69%); from 6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4f, 24.9 mg, 0.086 mmol) and 4-fluorobenzoyl chloride (20.5 μ L, 0.17 mmol); HRMS-FAB⁺ for C₂₁H₁₈N₂OBrF: calculated MH⁺: 413.06647; found: 413.06465.

30

(iii) 5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-thiophenecarbonyl)indole: (13.5 mg, 30%), from 5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4b, 30.9 mg, 0.134 mmol) and 2-thiophenecarbonyl chloride (23.6 mg, 0.16 mmol); HRMS FAB⁺ for C₁₉H₁₈N₂OSF calculated MH⁺: 341.11240; found: 341.11120.

(jjj) 1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole hydrochloride: (20 mg, 59%) from 5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4d, 25 mg, 0.1 mmol) and benzoyl chloride (21.1 mg, 0.15 mmol), m.p 256-7 °C, HRMS-FAB⁺ for C₂₁H₁₉N₂OCl·HCl, calculated MH⁺(-HCl): 351.1264; found: 351.12595.

(kkk) 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: (9.3 mg, 32%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and benzoyl chloride (15.0 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₉N₂O₂F₃, calculated MH⁺: 401.14767; found: 401.14761.

- (III) 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: (19.2 mg, 59%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-fluorobenzoyl chloride (17.0 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₈N₂O₂F₄·HCl, calculated MH⁺(-HCl): 419.13828; found: 419.13870.
- (mmm) 1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: (22.2 mg, 67%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 4-methoxybenzoyl chloride (18.3 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₃H₂₁N₂O₃F₃·HCl, calculated MH⁺(-HCl): 431.15826; found: 431.15694.
- (nnn) 1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole: (14.3 mg, 43%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxy-1H-indole (Example 4h, 20 mg, 0.068 mmol) and 2,6-dichlorobenzoyl chloride (22.4 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₇N₂O₂ClF₃, calculated MH⁺: 469.06973; found: 469.07199.
- (ooo) 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride: (20.3 mg, 74%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and benzoyl chloride (15.0 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₉N₂OF₃, calculated MH⁺: 385.15277; found: 385.15480.
- (ppp) 1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole: (22.8 mg, 79%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and 4-fluorobenzoyl chloride (17.0 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₈N₂OF₄, calculated MH⁺(-HCl): 403.14344; found: 403.14104.
- (qqq) 1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole: (25.2 mg, 78%); from 3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethyl-1H-indole (Example 4i, 20 mg, 0.071 mmol) and

2,6 dichlorobenzoyl chloride (18.3 mg, 0.107 mmol), HRMS-FAB⁺ for C₂₂H₁₈N₂OCl₂F₃, calculated MH⁺(-HCl): 453.07483; found: 453.07779.

- (rrr) 5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-4-piperidiny)indole (12.0 mg, 51%); from 5-cyclohexyloxy-3-(1-methyl-4-piperidiny)-1H-indole (Example 5a, 15.7 mg, 0.05 mmol) and 4-methylphenylsulfonyl chloride (50 mg, 0.26 mmol); HRMS-FAB⁺ for C₂₇H₃₄N₂O₃S: calculated MH⁺: 467.23685; found: 467.23882.
- 10 (sss) 5-Chloro-3-(1-methyl-4-piperidiny)-1-phenylsulfonylindole: (24.2 mg, 62%) from 5-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5e, 25 mg, 0.1 mmol) and phenylsulfonyl chloride (26.4 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₁N₂O₂SCl, calculated MH⁺(-HCl): 389.10904; found: 389.11246.
- 15 (ttt) 5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-4-piperidiny)indole (18.4 mg, 45%) from 5-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5e, 25 mg, 0.1 mmol) and 4-fluorophenylsulfonyl chloride (29.2 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₀N₂O₂SClF, calculated MH⁺: 407.09964; found: 407.09685.
- 20 (uuu) 3-(1-Methyl-4-piperidiny)-1-phenylsulfonylindole: (23.9 mg, 67%) from 3-(1-methyl-4-piperidiny)-1H-indole (Example 5d, 21.5 mg, 0.1 mmol) and phenylsulfonyl chloride (26.4 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₂N₂O₂S, calculated MH⁺: 355.14807; found: 355.15074.
- 25 (vvv) 1-(4-Fluorophenylsulfonyl)-3-(1-methyl-4-piperidiny)indole: (17.0 mg, 46%), from 3-(1-methyl-4-piperidiny)-1H-indole (Example 5d, 21.5 mg, 0.1 mmol) and 4-fluorophenylsulfonyl chloride (29.2 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₁N₂O₂SF, calculated MH⁺: 373.13861; found: 373.13669.

30

(www) 6-Chloro-3-(1-methyl-4-piperidiny)-1-phenylsulfonylindole: (35.9 mg, 92%), from 6-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5b, 25 mg, 0.1 mmol) and phenylsulfonyl chloride (26.4 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₁N₂O₂SCl, calculated MH⁺: 389.10904; found: 389.11055.

5

(xxx) 1-(4-Fluorophenylsulfonyl)-6-chloro-3-(1-methyl-4-piperidiny)indole: (26.8 mg, 65%), from 6-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5b, 25 mg, 0.10 mmol) and 4-fluorophenylsulfonyl chloride (29.2 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₀N₂O₂SClF, calculated MH⁺: 407.09964; found:

10 407.09929.

(yyy) 5-Fluoro-1-phenylsulfonyl-3-(1-methyl-4-piperidiny)indole: (27.3 mg, 73%) from 5-fluoro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5c, 25 mg, 0.1 mmol) and phenylsulfonyl chloride (26.4 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₀H₂₁N₂O₂SF, calculated MH⁺: 373.13861; found: 373.13569.

15

(zzz) 1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-4-piperidiny)indole: (22.6 mg, 58%) from 5-fluoro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5c, 25 mg, 0.1 mmol) and 4-fluorophenylsulfonyl chloride (29.2 mg, 0.15 mmol), HRMS- FAB⁺ for C₂₀H₂₀N₂O₂SF₂, calculated MH⁺: 391.12918; found: 391.12926.

20

(ab) 1-Benzoyl-5-chloro-3-(1-methyl-4-piperidiny)indole: (23.0 mg, 65%); from 5-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5e, 25 mg, 0.10 mmol) and benzoyl chloride (21.1 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₁N₂OCl, calculated MH⁺: 353.14206; found: 353.14033.

25

(ac) 5-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidiny)indole: (22.5 mg, 61%); from 5-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5e, 25 mg, 0.10 mmol) and 4-fluorobenzoyl chloride (23.8 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₀N₂OCIF, calculated MH⁺: 371.13263; found: 371.13063.

30

(ad) 1-Benzoyl-3-(1-methyl-4-piperidiny)indole: (28.1 mg, 88%); from 3-(1-

- methyl-4-piperidiny)-1H-indole (Example 5d, 21.5 mg, 0.10 mmol) and benzoyl chloride (21.1 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₁N₂O, calculated MH⁺: 319.18103; found: 319.18293.
- 5 (ae) 1-(4-Fluorobenzoyl)-3-(1-methyl-4-piperidiny)indole: (27.2 mg, 81%); from 3-(1-methyl-4-piperidiny)-1H-indole (Example 5d, 21.5 mg, 0.10 mmol) and 4-fluorobenzoyl chloride (23.8 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₁N₂OF, calculated MH⁺: 337.17163; found: 337.17162.
- 10 (af) 1-Benzoyl-6-chloro-3-(1-methyl-4-piperidiny)indole: (25.4 mg, 72%); from 6-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5b, 25 mg, 0.10 mmol) and benzoyl chloride (21.1 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₁ClN₂O, calculated MH⁺: 353.14206; found: 353.13873.
- 15 (ag) 6-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidiny)indole: (21.8 mg, 60%); from 6-chloro-3-(1-methyl-4-piperidiny)-1H-indole (Example 4b, 25 mg, 0.10 mmol) and 4-fluorobenzoyl chloride (23.8 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₀N₂OCIF, calculated MH⁺: 371.13263; found: 371.13266.
- 20 (ah) 1-Benzoyl-5-fluoro-3-(1-methyl-4-piperidiny)indole: (24.0 mg, 71%); from 5-fluoro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5c, 23.0 mg, 0.10 mmol) and benzoyl chloride (21.1 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₁N₂OF, calculated MH⁺: 337.17163; found: 337.16994.
- 25 (ai) 1-(4-Fluorobenzoyl)-5-fluoro-3-(1-methyl-4-piperidiny)indole: (25.1 mg, 71%); from 5-fluoro-3-(1-methyl-4-piperidiny)-1H-indole (Example 5c, 23.0 mg, 0.10 mmol) and 4-fluorobenzoyl chloride (23.8 mg, 0.15 mmol), HRMS-FAB⁺ for C₂₁H₂₀N₂OF₂, calculated MH⁺: 355.16220; found: 355.16313.
- 30 (aj) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1-phenylsulfonylindole: (8.5 mg, 54%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridiny)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and phenylsulfonylchloride (10.6 mg, 0.06 mmoles) with 1M NaN(TMS)₂ (60 μL,

0.06mmol) in THF (0.5 mL) at RT.

(ak) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole: (8.8 mg, 54%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 4-methylphenylsulfonyl chloride (11.4 mg, 0.06 mmoles) with 1M NaN(TMS)₂ (60 μ L, 0.06 mmol) in THF (0.5 mL) at RT.

(al) 5,7-Difluoro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (7.6 mg, 46.4%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmoles) and 4-fluorophenylsulfonyl chloride (11.7 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μ L, 0.06 mmoles) in THF (0.5 mL) at RT.

(am) 1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (8.7 mg, 48%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 4-bromophenylsulfonyl chloride (15.3 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μ L, 0.06 mmol) in THF (0.5 mL) at RT.

(an) 1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (6.7mg, 39%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04mmol) and 4-chlorophenylsulfonyl chloride (12.7 mg, 0.06 mmoles) with 1M NaN (TMS)₂ (60 μ L, 0.06 mmol) in THF (0.5 mL) at RT.

(ao) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole: (9.2 mg, 52%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 1-naphthalenesulfonyl chloride (13.6 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μ L, 0.06 mmol) in THF (0.5 mL) at RT.

(ap) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-

naphthylsulfonyl)indole: (5.1 mg, 29%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 2-naphthalenesulfonyl chloride (13.6 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μL, 0.06 mmol) in THF (0.5 mL) at RT.

5

(aq) 5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenyl)sulfonylindole: (5.7 mg, 33%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 2,4,6-trimethylphenylsulfonyl chloride (13.1 mg, 0.06 mmol) with 1M

10 NaN(TMS)₂ (60 μL, 0.06 mmol) in THF (0.5 mL).

(ar) 5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (6.3 mg, 42%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 4-fluorobenzoyl chloride (9.5 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μL, 0.06 mmol) in THF (0.5 mL) at RT.

15

(as) 1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole: (5.6 mg, 33%); from 5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole (Example 4g, 10 mg, 0.04 mmol) and 2,5-dichlorobenzoyl chloride (12.6 mg, 0.06 mmol) with 1M NaN(TMS)₂ (60 μL, 0.06 mmol) in THF (0.5 mL) at RT.

20

Example 8: 1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-vinylindole

25

Tributylvinylstannane was added to a solution of 1-benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole (Example 6g) in DMF and the reaction mixture was heated to 100 °C overnight. The mixture was partitioned between ethyl acetate and water, sequentially washed with water and brine, and dried over sodium carbonate. Flash chromatography (silica gel, 5% 2M methanolic ammonia in dichloromethane) yielded 1-benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-vinylindole.

30

Example 13: Binding Affinity for the 5-HT₆ Receptor

All of the compounds of the invention were evaluated using cell types receptive specifically to the 5-HT₆ receptor (for cloning and characterization of the human 5-HT₆ receptor see Kohen, *et al.* J. Neurochemistry, 66, 1996: 47-56). The assay protocol generally entailed the incubation of membranes prepared from cells expressing the 5-HT₆ receptor with ³H-LSD. Increasing levels of the test compound were incubated with the radioligand and the membrane homogenates prepared from the recombinant cells. After a 60 minute incubation at 37 °C, the incubation was terminated by vacuum filtration. The filters were washed with buffer and the filters were counted for radioactivity using liquid scintillation spectrometry. The affinity of the test compound for the 5-HT₆ receptor was determined by computer-assisted analysis of the data and determining the amount of the compound necessary to inhibit 50% of the binding of the radioligand to the receptor. Concentrations ranging from 10⁻¹¹ M to 10⁻⁵ M of the test compound were evaluated. For comparison, the affinity of clozapine for the 5-HT₆ receptor (K_i ~ 3 nM) was used as a standard. All of the compounds of the invention exhibited affinity for the human 5-HT₆ receptor, with K_i's of not greater than 1000 nM. Preferred compounds, those of examples 6b, 6c, 6f, 6g, 7a, 7b, 7c, 7d, 7e, 7f, 7g, 7i, 7j, 7l, 7m, 7bb, 7cc, 7dd, 7gg, 7ii, 7jj, 7kk, 7oo, 7pp, 7rr, 7vv, 7ww, 7aaa, 7jjj, 7qqq, 7uuu, 7aj, 7ak, 7am, 7an, 7ao, 7ap, 7ar and 7as, exhibited K_i's of not greater than 50 nM. Particularly preferred compounds, those of examples 6b, 6c, 6f, 7a, 7c, 7bb, 7cc, 7dd, 7gg, 7ii, 7jj, 7kk, 7oo, 7pp, 7rr, 7aaa, 7aj, 7ak, 7am, 7an, 7ao, 7ap and 7ar, exhibited K_i's of not greater than 5 nM. The compounds of the invention also bound to the human 5-HT₆ receptor in a selective manner, relative to the human 5-HT_{2C} and 5-HT₇ receptors. That is, the compounds of the invention bound to the human 5-HT₆ receptor with at least a 2-fold greater affinity, relative to the human 5-HT_{2C} and 5-HT₇ receptors. Preferred compounds, for example, those of examples 6b, 6g, 7i, 7m, 7bb, 7dd, 7gg, 7hh, and 7ii, bound to the human 5-HT₆ receptor with at least a 60-fold greater affinity, relative to the human 5-HT_{2C} and 5-HT₇ receptors. More preferred compounds, for example, those of

examples 7m, 7gg and 7ii, bound to the human 5-HT₆ receptor with at least a 300-fold greater affinity, relative to the human 5-HT_{2C} and 5-HT₇ receptors.

5 Example 14: Effect of Compounds on the cAMP Response of Human 5-HT₆ Receptors

The antagonist (or agonist) property of compounds for human 5-HT₆ receptors was determined by testing their effect on cAMP accumulation in stably transfected HEK293 cells.

10

Binding of an agonist to the human 5-HT₆ receptor will lead to a increase in adenyl cyclase activity. A compound which is an agonist will show an increase in cAMP production and a compound which is an antagonist will block the agonist effect.

15

Cell Assay: Human 5-HT₆ receptors were cloned and stably expressed in HEK293 cells. These cells were plated in 6 well plates in DMEM/F12 media with 10% fetal calf serum (FCS) and 500 µg/mL G418 and incubated at 37°C in a CO₂ incubator. The cells were allowed to grow to about 70% confluence before initiation of the experiment.

20

On the day of the experiment, the culture media was removed, and the cells were washed once with serum free medium (SFM). Two mL of SFM+IBMX media was added and incubated at 37°C for 10 min. The media were removed and fresh SFM+IBMX media containing various compounds, and 1 µM serotonin (as antagonist) were added to the appropriate wells and incubated for 30 min. Following incubation, the media were removed and the cells were washed once with 1 mL of PBS (phosphate buffered saline). Each well was treated with 1 mL cold 95% ethanol and 5 mM EDTA (2:1) at 4°C for 1 hour. The cells were then scraped and transferred into Eppendorf tubes. The tubes were centrifuged for 5 min at 4°C, and the supernatants were stored at 4 °C until assayed.

25

30

cAMP Measurement: cAMP content was determined by EIA (enzyme-immunoassay) using the Amersham Biotrak cAMP EIA kit (Amersham RPN 225). The procedure used is as described for the kit. Briefly, cAMP is determined by the competition between unlabeled cAMP and a fixed quantity of peroxidase-labelled cAMP for the binding sites on anti-cAMP antibody. The antibody is immobilized onto polystyrene microtitre wells precoated with a second antibody. The reaction is started by adding 50 μ L peroxidase-labeled cAMP to the sample (100 μ L) preincubated with the antiserum (100 μ L) for 2 hours at 4 $^{\circ}$ C. Following 1 hour incubation at 4 $^{\circ}$ C, the unbound ligand is separated by a simple washing procedure. Then an enzyme substrate, tetramethylbenzidine (TMB), is added and incubated at room temperature for 60 min. The reaction is stopped by the addition of 100 μ L 1.0 M sulfuric acid and the resultant color read by a microtitre plate spectrophotometer at 450 nM within 30 minutes.

15


All of the compounds of the invention which were tested in the above assays were found to be antagonists. The potency of compounds of the invention as antagonists is expressed as an EC_{50} , which is the concentration causing 50% inhibition of the serotonin-stimulated cAMP response. The table below presents the EC_{50} 's of some of the compounds of the invention compared to clozapine as a reference compound.

20

Example #	EC ₅₀ (M)
clozapine	9.5×10^{-9}
6cc	1.0×10^{-8}
5b	1.9×10^{-6}

We Claim:

1. A compound according to Formula I and salts, solvates or hydrates thereof:



wherein:

R^1 is selected from the group consisting of H and C_{1-4} alkyl;

R^2 is selected from the group consisting of H, C_{1-4} alkyl and benzyl;

----- represents a single or double bond;

R^3 is selected from the group consisting of COR^5 and SO_2R^5 ;

R^{4a} is selected from the group consisting of H, OH, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{4b} is selected from the group consisting of H, hydroxy, halo, C_{3-7} cycloalkyloxy, C_{1-4} alkoxy, C_{1-4} alkyl, benzyloxy, phenoxy, trifluoromethyl, trifluoromethoxy and vinyl;

R^{4c} is selected from the group consisting of H, OH, halo, C_{1-4} alkyl and C_{1-4} alkoxy;

R^{4d} is selected from the group consisting of H, OH, halo, C_{1-4} alkyl and C_{1-4} alkoxy; and

R^5 is selected from the group consisting of phenyl, pyridyl, thienyl, quinoliny and naphthyl which are optionally substituted with 1-4 substituents selected from C_{1-4} alkoxy, C_{1-4} alkyl, halo, nitro, trifluoromethyl, trifluoromethoxy, 1,2-methylenedioxy, C_{1-4} alkylcarbonyl, C_{1-4} alkoxycarbonyl and C_{1-4} alkylS-.

2. A compound according to claim 1, wherein R^1 is methyl.

3. A compound according to claim 1, wherein R^2 is H.
4. A compound according to claim 1, wherein R^3 is COR^5
5. A compound according to claim 4, wherein R^5 is selected from phenyl and thienyl optionally substituted with 1-2 groups selected independently from methyl, methoxy, halo and 1,2-methylenedioxy.
6. A compound according to claim 5, wherein R^5 is phenyl optionally substituted with 1-2 groups selected independently from halo, methoxy and methyl.
7. A compound according to claim 1, wherein R^3 is SO_2R^5 .
8. A compound according to claim 7, wherein R^5 is selected from the group consisting of phenyl, naphthyl and thienyl which are all optionally substituted with 1-3 groups selected independently from methyl, methoxy, halo, trifluoromethyl and 1,2-methylenedioxy.
9. A compound according to claim 8, wherein R^5 is selected from the group consisting of naphthyl and phenyl optionally substituted with 1-3 substituents independently selected from chloro, bromo, fluoro, nitro, methyl and methoxy.
10. A compound according to claim 9, wherein R^5 is selected from the group consisting of phenyl, 2-chlorophenyl, 2-bromophenyl, 1-naphthyl, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 2,4-dichlorophenyl, 3-nitro-4-chlorophenyl, 2,4,6-trimethylphenyl, 4-methoxyphenyl and 4-methylphenyl.
11. A compound according to claim 1, wherein R^{4a} , R^{4c} and R^{4d} are H and R^{4b} is selected from H, halo, methyl, trifluoromethyl and methoxy.

12. A compound according to claim 1, wherein R^{4b} and R^{4d} are halo.
13. A compound according to claim 1, wherein ---- represents a double bond.
14. A compound according to claim 1, which is selected from:
- 1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole;
5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
6-Bromo-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-triisopropylphenylsulfonyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
1-(4-Chloro-3-nitrophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitro-4-trifluoromethylphenylsulfonyl)indole;
1-(4-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

1-(4-t-Butylphenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-t-Butylphenylsulfonyl)-4-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethoxyindole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-

trifluoromethylindole hydrochloride;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-t-Butylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(2,6-dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(3,4-methylenedioxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Cyclohexyloxy-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-6-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
6-Bromo-1-(4-methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
6-Bromo-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-thienoyl)indole;
1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole hydrochloride;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;

1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Methoxybenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole;
5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
5-Chloro-3-(1-methyl-4-piperidinyl)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
3-(1-Methyl-4-piperidinyl)-1-phenylsulfonylindole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-4-piperidinyl)indole;
6-Chloro-3-(1-methyl-4-piperidinyl)-1-phenylsulfonylindole;
1-(4-Fluorophenylsulfonyl)-6-chloro-3-(1-methyl-4-piperidinyl)indole;
5-Fluoro-1-phenylsulfonyl-3-(1-methyl-4-piperidinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
1-Benzoyl-5-chloro-3-(1-methyl-4-piperidinyl)indole;
5-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
1-Benzoyl-3-(1-methyl-4-piperidinyl)indole;
1-(4-Fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
1-Benzoyl-6-chloro-3-(1-methyl-4-piperidinyl)indole;
6-Chloro-1-(4-fluorobenzoyl)-3-(1-methyl-4-piperidinyl)indole;
1-Benzoyl-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
1-(4-Fluorobenzoyl)-5-fluoro-3-(1-methyl-4-piperidinyl)indole;
1-Benzoyl-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-vinylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole;

5,7-Difluoro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenyl)sulfonylindole;
5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole; and
1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.

15. A compound according to claim 1, which is selected from:

1-Benzoyl-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-5-bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-1-(2,5-dichlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

1-(4-Chloro-3-nitrophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2,4,6-trimethylphenylsulfonyl)indole;

5-Cyclohexyloxy-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

6-Bromo-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;

6-Bromo-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;

5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;

5-Cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;

1-(2-Bromophenylsulfonyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

5-Cyclohexyloxy-1-(4-methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(3-nitrophenylsulfonyl)indole;

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;

5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;

5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;

5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Methoxyphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole hydrochloride;
1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-Benzoyl-5-chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole hydrochloride;
1-(2,6-Dichlorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethylindole;
3-(1-Methyl-4-piperidinyl)-1-phenylsulfonylindole;
6-Chloro-3-(1-methyl-4-piperidinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole;
1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;

5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole; and
1-(2,5-Dichlorobenzoyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.

16. A compound according to claim 1, which is selected from:

5-Fluoro-1-(4-methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Chlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2,6-Dichlorobenzoyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
1-(4-Fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(2-Bromophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Fluorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5-fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5-Fluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5-Chloro-1-(4-fluorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
1-(4-Methylphenylsulfonyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-5-trifluoromethoxyindole;
3-(1-Methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonyl-5-trifluoromethylindole hydrochloride;
1-(2-Chlorobenzoyl)-5-cyclohexyloxy-3-(1-methyl-1,2,3,6-tetrahydro-4-

pyridinyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-phenylsulfonylindole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(4-methylphenylsulfonyl)indole;
1-(4-Bromophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
1-(4-Chlorophenylsulfonyl)-5,7-difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(1-naphthylsulfonyl)indole;
5,7-Difluoro-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)-1-(2-naphthylsulfonyl)indole; and
5,7-Difluoro-1-(4-fluorobenzoyl)-3-(1-methyl-1,2,3,6-tetrahydro-4-pyridinyl)indole.

17. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and, in an amount effective to antagonize the 5-HT₆ receptor, a compound of Formula I.

18. A pharmaceutical composition, comprising a pharmaceutically acceptable carrier and, in an amount effective to antagonize the 5-HT₆ receptor, a compound of according to claim 14.

19. A method for treating a patient having a medical condition for which a 5-HT₆ receptor antagonist is indicated, comprising the step of administering to the patient a pharmaceutical composition as defined in claim 17.

20. A method for treating a patient according to claim 19, wherein the medical condition is schizophrenia.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 99/00342

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/04

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^o	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 47302 A (AUDIA JAMES E ; KOCH DANIEL J (US); LILLY CO ELI (US); MABRY THOMAS) 18 December 1997 (1997-12-18) the whole document ---	1-20
Y	EP 0 200 322 A (LUNDBECK & CO AS H) 5 November 1986 (1986-11-05) the whole document ---	1-20
Y	EP 0 465 398 A (LUNDBECK & CO AS H) 8 January 1992 (1992-01-08) the whole document ---	1-20
Y	WO 92 13856 A (PFIZER) 20 August 1992 (1992-08-20) the whole document ---	1-20
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

^o Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
 "E" earlier document but published on or after the international filing date
 "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
 "O" document referring to an oral disclosure, use, exhibition or other means
 "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
 "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
 "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
 "&" document member of the same patent family

Date of the actual completion of the international search

20 December 1999

Date of mailing of the international search report

16/02/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Stellmach, J

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 99/00342

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	MONSMA ET AL: "Cloning and Expression of A Novel Serotonin Receptor with High Affinity for Tricyclic Psychotropic Drugs" MOLECULAR PHARMACOLOGY,US,BALTIMORE, MD, vol. 43, no. 3, page 320-327 XP002093842 ISSN: 0026-895X the whole document ---	1-20
Y	SAUDOU F ET AL: "5-HT RECEPTOR SUBTYPES: MOLECULAR AND FUNCTIONAL DIVERSITY" MEDICINAL CHEMISTRY RESEARCH,US,BIRKHAUSER, BOSTON, vol. 4, no. 1, page 16-84 XP000604196 ISSN: 1054-2523 the whole document ---	1-20
Y	SLEIGHT ET AL: "The 5-hydroxytryptamine-6 receptor: localisation and function" EXPERT OPINION ON THERAPEUTIC PATENTS,GB,ASHLEY PUBLICATIONS, vol. 8, no. 10, page 1217-1224 XP002093843 ISSN: 1354-3776 the whole document ---	1-20
Y	MARTIN G R ET AL: "The structure and signalling properties of 5-HT receptors: an endless diversity?" TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 19, no. 1, page 2-4 XP004107578 ISSN: 0165-6147 the whole document ---	1-20
Y	HOYER D AND MARTIN G: "5-HT receptor classification and nomenclature: towards a harmonization with the human genome" NEUROPHARMACOLOGY,GB,PERGAMON PRESS, OXFORD, no. 36, page 419-428 XP002075372 ISSN: 0028-3908 the whole document ---	1-20
Y	HOYER D ET AL: "VII. INTERNATIONAL UNION OF PHARMACOLOGY CLASSIFICATION OF RECEPTORS FOR 5-HYDROXYTRYPTAMINE (SEROTONIN)" PHARMACOLOGICAL REVIEWS,US,WILLIAMS AND WILKINS INC., BALTIMORE, MD,, vol. 46, no. 2, page 157-203 XP000604197 ISSN: 0031-6997 the whole document -----	1-20

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00342

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9747302 A	18-12-1997	AU 3390797 A CA 2256649 A EP 0812826 A US 5846982 A	07-01-1998 18-12-1997 17-12-1997 08-12-1998
EP 0200322 A	05-11-1986	CA 1338327 B AU 583607 B CA 1256437 A DK 157686 A DK 169674 B FI 861505 A,B FI 90976 C HK 116793 A IE 58370 B JP 1885645 C JP 6004587 B JP 61236764 A LU 90218 A US RE34299 E US 4710500 A AT 50564 T ES 553807 A GR 860927 A IL 78136 A LV 5743 A MX 9203347 A NO 861235 A,B NZ 215507 A PT 82348 A,B	14-05-1996 04-05-1989 27-06-1989 11-10-1986 09-01-1995 11-10-1986 25-04-1994 05-11-1993 08-09-1993 22-11-1994 19-01-1994 22-10-1986 27-04-1998 29-06-1993 01-12-1987 15-03-1996 01-08-1987 29-07-1986 12-07-1990 20-10-1996 01-08-1992 13-10-1986 29-11-1988 01-05-1986
EP 0465398 A	08-01-1992	AT 115576 T AU 644186 B AU 8014491 A CA 2045955 A DE 69105839 D DE 69105839 T DK 465398 T ES 2064973 T FI 913194 A GR 3015286 T HK 52195 A IE 65339 B IL 98495 A JP 4253976 A KR 9510163 B NO 178191 B NZ 238757 A PT 98168 A,B SG 19895 G US 5322851 A US 5457115 A US 5216001 A	15-12-1994 02-12-1993 02-01-1992 03-01-1992 26-01-1995 27-04-1995 22-05-1995 01-02-1995 03-01-1992 30-06-1995 13-04-1995 18-10-1995 29-06-1995 09-09-1992 11-09-1995 30-10-1995 26-08-1993 29-05-1992 18-08-1995 21-06-1994 10-10-1995 01-06-1993
WO 9213856 A	20-08-1992	AT 135005 T AU 655456 B AU 1263792 A CZ 9301656 A DE 69208868 D	15-03-1996 22-12-1994 07-09-1992 18-05-1994 11-04-1996

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 99/00342

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9213856 A		DE 69208868 T	17-10-1996
		DK 571471 T	01-04-1996
		EP 0571471 A	01-12-1993
		ES 2084347 T	01-05-1996
		FI 933551 A	11-08-1993
		GR 3019778 T	31-07-1996
		HU 65766 A	28-07-1994
		JP 7121942 B	25-12-1995
		JP 6500122 T	06-01-1994
		MX 9200569 A	01-08-1992
		NO 932859 A	11-08-1993
		NZ 241584 A	22-12-1994
		PT 100114 A	31-05-1993
		ZA 9200969 A	11-08-1993
